X4 Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by X4 Pharmaceuticals, Inc. on October 18, 2023, covering events occurring on October 16, 2023. The filing primarily addresses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Keith Woods as a member of the Board of Directors, effective October 16, 2023. Mr. Woods will serve as a Class II director until the 2025 Annual Meeting of Stockholders. He has not been assigned to any Board committees at this time.
Compensation and Equity Grant
In connection with his appointment, Mr. Woods received an initial equity award of 90,000 restricted stock units (RSUs). The terms of the award are as follows:
- Term: Ten years from the date of grant.
- Vesting Schedule: Three equal installments on each of the first three anniversaries of the grant date, subject to continued service.
- Acceleration: 100% of the RSUs vest upon a change in control of the Company.
- Other Compensation: Mr. Woods will be compensated in accordance with the Company's standard arrangements for non-employee directors.
Outlook, Risks, and Contingencies
The filing does not contain management commentary on business outlook, specific risks, or contingencies beyond the standard disclosure that the press release furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Keith Woods was appointed to the Board of Directors on October 16, 2023.
- Mr. Woods received 90,000 RSUs as an initial equity award.
- The RSUs vest over three years with full acceleration upon a change in control.
- Mr. Woods has no family relationships with current directors or officers and no material interest in undisclosed transactions.
- The filing does not include updated financial statements or operational metrics.